A 27B Gemma‑based model trained on transcriptomics and bio text hypothesized that inhibiting CK2 (via silmitasertib) would enhance MHC‑I antigen presentation—making tumors more visible to the immune system. Yale labs tested the prediction and confirmed it in vitro, and are now probing the mechanism and related hypotheses.
— If small, domain‑trained LLMs can reliably generate testable, validated biomedical insights, AI will reshape scientific workflow, credit, and regulation while potentially speeding new immunotherapy strategies.
BeauHD
2026.04.17
90% relevant
This article reports an LLM (GPT‑Rosalind) tuned specifically for biological workflows that claims 'expert‑level' reasoning and the ability to suggest biological pathways and drug targets — the same vector as prior cases where LLMs produced novel, actionable biomedical hypotheses (e.g., claims that LLMs can surface valid molecular mechanisms). The actor (OpenAI), the model name (GPT‑Rosalind), and the claimed outputs (pathway inference, drug‑target prioritization) directly map to that existing idea.
BeauHD
2026.01.15
68% relevant
Existing idea documents an LLM hypothesizing a verifiable biomedical mechanism later validated by labs; the Slashdot story is an analogous math example (LLM proposing proofs later formalized/checked), showing the pattern extends across disciplines.
Steve Hsu
2025.12.02
70% relevant
This prior idea records LLMs producing testable, validated scientific hypotheses; Hsu's report extends that pattern into theoretical physics (GPT‑5 originating the main idea), showing the phenomenon is cross‑disciplinary and not limited to biomedical lab leads.
Alexander Kruel
2025.10.16
100% relevant
Google’s report that the Yale team validated the model’s CK2→MHC‑I prediction and is expanding testing of AI‑generated hypotheses.